Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C3H9O6P |
| Molecular Weight | 172.0737 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC(O)COP(O)(O)=O
InChI
InChIKey=AWUCVROLDVIAJX-UHFFFAOYSA-N
InChI=1S/C3H9O6P/c4-1-3(5)2-9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)
| Molecular Formula | C3H9O6P |
| Molecular Weight | 172.0737 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
DOI: 10.1042/bj0280143
DOI: 10.1042/bj0280152
http://www.wikidoc.org/index.php/Glycerol_3-phosphate
Curator's Comment: description was created based on several sources, including:
DOI: 10.1042/bj0280143
DOI: 10.1042/bj0280152
http://www.wikidoc.org/index.php/Glycerol_3-phosphate
Synthetic glycerophosphates have been known for many years and have been prepared in several ways. The acid may exist in two isomeric forms, alpha and beta. The L-a-acid is the naturally occurring form; the b-acid, present in hydrolyzates of lecithins from natural sources, arises from migration of the phosphoryl group from the a-carbon atom. Dehydrogenation of L-glycerol 3-phosphate produces Dihydroxyacetone phosphate and is part of the entry of glycerol (sourced from triglycerides) into the glycolytic pathway.
CNS Activity
Originator
Curator's Comment: alpha-glycerophosphoric acid has long been known as a component of the lecithins and cephalins and may in a sense be looked on as a monoglyceride, the situation is much more favorable. Because of its great stability it has been possible for several workers to separate it from various phosphatides and free it from its accompanying beta-isomer. http://www.jbc.org/content/128/2/491.short
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: 2819.0 Gene Symbol: GPD1 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | KABIVEN Approved UseIt is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Launch Date2014 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.87 mM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21986180/ |
80 mmol single, intravenous dose: 80 mmol route of administration: Intravenous experiment type: SINGLE co-administered: |
PHOSPHATE ION serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
38.7 mM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21986180/ |
80 mmol single, intravenous dose: 80 mmol route of administration: Intravenous experiment type: SINGLE co-administered: |
PHOSPHATE ION serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.06 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21986180/ |
80 mmol single, intravenous dose: 80 mmol route of administration: Intravenous experiment type: SINGLE co-administered: |
PHOSPHATE ION serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [IN VITRO EFFECT OF ALPHA GLYCEROPHOSPHATE ON RELEASE OF NON-ESTERIFIED FATTY ACIDS FROM ADIPOSE TISSUE]. | 1965-06 |
|
| [Pharmacology of glycerophosphoric acid. II. Differences in the biological action of the alpha and beta isomers in combination with thiamine or cocarboxylase]. | 1955-12-01 |
|
| alpha-Glycerophosphoric acid and brain metabolism. | 1936-01 |
Patents
Sample Use Guides
19 to 38 mL/kg/day. The maximum infusion rate is 2.6 mL/kg/hour. Recommended infusion period is 12 to 24 hours.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7492326
Maximal ATP production in the presence of Ca2+ (200 nM) is obtained at 10 mM L-glycerol 3-phosphate in intact mitochondria from pancreatic B-cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:34:59 GMT 2025
by
admin
on
Mon Mar 31 17:34:59 GMT 2025
|
| Record UNII |
9NTI6P3O4X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
200-307-1
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | |||
|
9NTI6P3O4X
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | |||
|
DTXSID6023105
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | |||
|
m5792
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
9231
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | |||
|
C029620
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | |||
|
GLYCEROL 3-PHOSPHATE
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | |||
|
14336
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | |||
|
754
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | |||
|
231935
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY | |||
|
57-03-4
Created by
admin on Mon Mar 31 17:34:59 GMT 2025 , Edited by admin on Mon Mar 31 17:34:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |